Spyre Therapeutics (SYRE) investor relations material

Strategic positioning and pipeline overview

• Focused on developing optimized, best-in-class biologics targeting α4β7, TL1A, and IL-23 for autoimmune diseases, with initial emphasis on inflammatory bowel disease (IBD) and rheumatology indications.

• Six phase II readouts are expected within the next nine months, including three placebo-controlled readouts from the SKYWAY trial and additional TL1A data from other companies.

• Combination therapies are prioritized, leveraging the safety and additive efficacy of selected mechanisms, aiming for indication-leading products.

• Portfolio design avoids weak components, with all antibodies optimized for safety, efficacy, and half-life extension.

• TL1A is highlighted as a potential game-changer, with next-generation antibodies positioned to capture significant market opportunities.

Clinical trial design and execution

• SKYLINE is a seamless platform trial in ulcerative colitis, testing three monotherapies and their combinations in both open-label (Part A) and placebo-controlled (Part B) settings.

• Open-label Part A enables site activation and protocol familiarization, accelerating Part B enrollment.

• Objective endpoints such as Robarts Histopathology Index and blinded endoscopy readings are used to ensure data integrity.

• Dose-ranging and contribution of components are assessed, with the goal to identify the most effective combination(s) for phase III advancement.

• Strategies to minimize placebo response include strict inclusion criteria and strong site engagement, leveraging experienced teams.

Competitive landscape and differentiation

• J&J’s DUET and VEGA studies inform expectations, with the belief that optimized combinations (e.g., α4β7 or TL1A with IL-23) will outperform less optimal TNF-based combos.

• Clinical meaningfulness is benchmarked at a 10% delta in clinical remission, based on precedent-setting head-to-head trials in IBD.

• The trial design avoids enrolling patients who have failed all components, differentiating from some competitors.

• Combination therapies are expected to set a new standard in IBD, with a top-down treatment paradigm anticipated.